News Category
NanoViricides expects to commence a Phase II clinical trial of its oral antiviral NV-387 for Ebola in the DRC, potentially offering a more accessible ...
GeoVax highlights its MVA-based hemorrhagic fever vaccine candidates and expertise as the Democratic Republic of Congo faces the fastest-growing Ebola...
NanoViricides has received approval to begin a Phase II trial of its oral antiviral NV-387 for Ebola in the DRC, potentially offering a more practical...
NanoViricides is awaiting regulatory approval in the Democratic Republic of the Congo to begin a Phase II clinical trial of its NV-387 Oral Gummies fo...
NanoViricides has applied for regulatory approval in the DRC to begin a Phase II trial of its oral antiviral NV-387 against the current Bundibugyo ebo...
NanoViricides received National Ethics Committee approval in the Democratic Republic of the Congo for a Phase II trial of its oral NV-387 gummies agai...
The Democratic Republic of Congo's copper and cobalt production remains resilient despite Middle East unrest affecting mining inputs, offering lessons...
NanoViricides moves its oral gummies formulation of NV-387 toward a Phase II trial for the Bundibugyo ebolavirus outbreak in the DRC, addressing a cri...
NanoViricides has shipped its broad-spectrum antiviral NV-387 to the Democratic Republic of Congo for a Phase II clinical trial targeting MPox, potent...
NanoViricides announced DRC regulatory approval to advance its Phase II Ebola trial for NV-387 Oral Gummies, the only oral Ebola treatment candidate u...
Redwood AI Corp. has signed a letter of intent to develop a regional pathogen tracking and AI-driven outbreak intelligence initiative in Central and E...
Trident Digital Tech Holdings Ltd. (NASDAQ: TDTH) has launched TDTHAI, an AI platform aimed at enterprise AI deployment, workflow automation, and digi...
The U.S. CDC has extended its travel ban on individuals from Uganda, South Sudan, and the DRC to include green card holders, raising concerns among he...
NanoViricides announces that its broad-spectrum antiviral NV-387 could be evaluated for the Bundibugyo Ebola outbreak, with its host-targeted mechanis...
NanoViricides underscores the potential of its oral drug candidate NV-387 as a pandemic preparedness tool against the ongoing Bundibugyo Ebola outbrea...
NanoViricides reported progress in its quarterly filing, highlighting regulatory approval for Phase II trials of NV-387 for MPox in the Democratic Rep...
The ongoing conflict in Iran is disrupting shipments of processing chemicals to cobalt and copper miners in the Democratic Republic of Congo, forcing ...
NanoViricides announced plans to begin a Phase II clinical trial of its antiviral candidate NV-387 for MPox in the Democratic Republic of Congo, with ...
Virtus Minerals, a US critical minerals company, acquires Chemaf, a DRC-based lithium and cobalt producer, signaling growing Western interest in secur...
Easy Environmental Solutions leverages its Terreplenish microbial solution to address the global nitrogen crisis, expanding production and trials acro...
NanoViricides announced completion of NV-387 Oral Gummies manufacturing for upcoming Phase II monkeypox trial and plans to present at NIBA Investment ...
The Democratic Republic of Congo has ended its 10-month ban on cobalt exports, underscoring the global market's fragility due to concentrated supply a...
Micropolis AI Robotics (NYSE American: MCRP) announced a $9.3 million, 18-month agreement with AfricAI Limited to design, develop, and distribute thre...
NanoViricides President Dr. Anil Diwan detailed the company's nanoviricide technology and lead candidate NV-387's potential to treat multiple viral di...
The Democratic Republic of Congo's suspension of cobalt exports in early 2025 to influence global prices is expected to create a supply deficit by 202...
